How to Test HER2 for Predicting Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer? Evidence From the Secondary Analysis of Biomarkers of CALGB/SWOG 80405
1 Andrea Sartore-Bianchi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Silvia Marsoni, MD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy; Alessio Amatu, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Valter Torri, MD, Department of Clinical Oncology, "Mario Negri" Institute for Pharmacological Research- IRCCS, Milan, Italy; Emanuela Bonoldi, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Alberto Bardelli, PhD, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy, Department of Oncology, Università degli Studi di Torino, Turin, Italy; Livio Trusolino, MD, Department of Oncology, Università degli Studi di Torino, Turin, Italy, Laboratory of Translational Cancer Medicine, Candiolo Cancer Institute-FPO IRCCS, Turin, Italy; Salvatore Siena, MD, Department of Hematology Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy, Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.